Corline Biomedical AB (CLBIO) — Cash Flow-to-Debt Ratio
Corline Biomedical AB (CLBIO) has a Cash Flow-to-Debt Ratio of -0.36x as of March 2026, meaning its operating cash flow of Skr-5.60 Million could theoretically repay 0% of its total liabilities (Skr15.53 Million) in one year. See CLBIO free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Corline Biomedical AB Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Corline Biomedical AB across 13 annual periods. For the full cash flow conversion analysis, see Corline Biomedical AB cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Corline Biomedical AB (2013–2025)
Year-by-year debt coverage analysis for Corline Biomedical AB. Check CLBIO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.67x | Skr-17.69 Million | Skr4.82 Million | ▼ -233.5% |
| 2024 | -1.10x | Skr-8.64 Million | Skr7.85 Million | ▼ -943.5% |
| 2023 | 0.13x | Skr886.00K | Skr6.79 Million | ▲ +114.6% |
| 2022 | -0.90x | Skr-6.45 Million | Skr7.19 Million | ▼ -74.9% |
| 2021 | -0.51x | Skr-4.83 Million | Skr9.43 Million | ▲ +36.7% |
| 2020 | -0.81x | Skr-5.07 Million | Skr6.25 Million | ▲ +74.0% |
| 2019 | -3.12x | Skr-13.84 Million | Skr4.43 Million | ▼ -505.0% |
| 2018 | -0.52x | Skr-4.10 Million | Skr7.95 Million | ▲ +43.0% |
| 2017 | -0.90x | Skr-4.98 Million | Skr5.50 Million | ▲ +68.3% |
| 2016 | -2.85x | Skr-7.21 Million | Skr2.53 Million | ▼ -152.3% |
| 2015 | -1.13x | Skr-4.23 Million | Skr3.74 Million | ▼ -450.0% |
| 2014 | -0.21x | Skr-2.32 Million | Skr11.29 Million | ▲ +57.1% |
| 2013 | -0.48x | Skr-2.76 Million | Skr5.76 Million | — |